NCT05275777 2025-07-25A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast CancerNational University Hospital, SingaporePhase 1/2 Active not recruiting66 enrolled